Faculty profile
Rob Holt
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
RNA-Seq Analysis of Gene Expression, Viral Pathogen, and B-Cell/T-Cell Receptor Signatures in Complex Chronic Disease.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.
The Journal of molecular diagnostics : JMD · 2013
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Nature · 2011
Latest funding
- $573,752
Understanding the immune response to the oncomicrobe Fusobacterium nucleaum
CIHR · 2026 · Nominated PI
- $3,051,528
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Co-investigator
- $762,882
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Co-investigator
3 publications.
RNA-Seq Analysis of Gene Expression, Viral Pathogen, and B-Cell/T-Cell Receptor Signatures in Complex Chronic Disease.
Bouquet J, Gardy JL, Brown S, Pfeil J, Miller RR, Morshed M, Avina-Zubieta A, Shojania K, McCabe M, Parker S, Uyaguari M, Federman S, Tang P, Steiner T, Otterstater M, Holt R, Moore R, Chiu CY, Patrick DM, Complex Chronic Disease Study Group
A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.
Bosdet IE, Docking TR, Butterfield YS, Mungall AJ, Zeng T, Coope RJ, Yorida E, Chow K, Bala M, Young SS, Hirst M, Birol I, Moore RA, Jones SJ, Marra MA, Holt R, Karsan A
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA
Understanding the immune response to the oncomicrobe Fusobacterium nucleaum
Principal investigators: Holt, Rob
Keywords: Antibodies; Colorectal Cancer; Fusobacterium Nucleatum; Microbiome; Oncomicrobe; Proteomics; Serology; T Cells; Tumour Progression; Vaccine
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
A Phase I first-in-human trial of CLIC-2201, a VHH-CD22 CAR-T cell product for the treatment of relapsed/refractory CD22 positive B-cell non-Hodgkin lymphoma
Principal investigators: Hay, Kevin A; Kekre, Natasha
Keywords: Adoptive Immunotherapy; Car-T Cells; Chimeric Antigen Receptor; Diffuse Large B-Cell Lymphoma (Dlbl); Non-Hodgkin'S Lymphoma; Phase I Clinical Trial
Lentiviral infusion as a universal approach for genetically modified immune effector cell therapies.
Principal investigators: Holt, Rob
Keywords: Cancer Immunotherapy; Car-T; Gene Expression; Gene Therapy; Gene Transfer Vectors; Immune Effector Cells; Lentivirus; Leukemia; Lymphoma; Synthetic Promoters
Joint Meeting of the Canadian Cancer Immunotherapy Consortium and ImmunoBC 2018
Principal investigators: Nelson, Brad H
Keywords: Cancer Immunotherapy; Cell Therapy; Immune Modulation; Immunotherapy; Knowledge Transfer; Mentorship; National Meeting; Vaccination
Engineering T cells to overcome an immunosuppressive solid tumour microenvironment
Principal investigators: Holt, Rob
Keywords: Adoptive Cell Transfer; Chimeric Antigen Receptor; Genetic Engineering; Immunotherapy; Natural Killer Cell; Pre-Clinical Models; Synthetic Biology; T Cell
Mechanisms of Protective Immunity in Ovarian Cancer
Principal investigators: Nelson, Brad H
Keywords: Antibodies; Antigens; Cd20+ B Cells; Cd8+ T Cells; Chemotherapy; Immunotherapy; Ovarian Cancer; Plasma Cells; Prognosis; Tumor-Infiltrating Lymphocytes
Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015
Principal investigators: Nelson, Brad H
Keywords: Antigens; Cancer Immunotherapy; Cell Therapy; Clinical Trials; Immune Modulation; Knowledge Transfer; Mentorship; National Meeting; Vaccination
Interrogating large-scale cancer genome datasets to aid in the development of personalized cancer immunotherapies.
Principal investigators: Brown, Scott D
Keywords: Bioinformatics; Cancer Immunology; Genomics; Immunogenomics; Immunotherapy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Genome Sciences Centre
- Microbiology and Immunology
- Pathology and Laboratory Medicine
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.